NCT07754019Completed
Serum and Urinary sCD163 in IgA Nephropathy
Association of Serum and Urinary Soluble CD163 Levels With Disease Activity, Histopathologic Severity, and Prognosis in Patients With IgA Nephropathy: A Single-Center Observational Study
Source: ClinicalTrials.gov · Last updated 27 Oct 2026
Brief summary (registry, in English)
IgA nephropathy is a common primary glomerular disease with a highly variable clinical course. Soluble CD163 is a marker associated with monocyte and macrophage activation and may reflect inflammatory activity in kidney disease. This single-center observational study aims to evaluate the associations of serum and urinary soluble CD163 levels with clinical disease activity, histopathologic severity, and renal prognosis in patients with IgA nephropathy. Clinical, laboratory, and kidney biopsy findings will be assessed together with serum and urinary soluble CD163 measurements. Participants will also be followed for renal outcomes, including changes in kidney function and proteinuria. The study is expected to clarify whether soluble CD163 may serve as a noninvasive biomarker of disease activity and prognosis in IgA nephropathy.
- Status (registry)
- Completed
- Study type
- Observational
- Enrollment
- 87 (actual)
- First submitted
- 4 Aug 2026
- Start date
- 3 Feb 2025
- Primary completion date
- 1 Sept 2026
- Lead sponsor
- Bezmialem Vakif University
- Diseases
- IgA nephropathy
- NCT number
- NCT07754019
What you commit to
- Study type: Observational
- Participants enrolled: 87
- From 3 Feb 2025 to the primary completion date, 1 Sept 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Recent use of corticosteroids or immunosuppressive therapy
Other illness
- Active infection
- End-stage kidney disease or ongoing dialysis treatment
- Active malignancy or history of malignancy
Lab values
- Inadequately stored or unavailable serum and/or urine samples
- Missing essential clinical, laboratory, histopathologic, or follow-up data
Other
- \- Secondary IgA nephropathy or secondary focal segmental glomerulosclerosis
- Acute kidney injury
- Estimated glomerular filtration rate below 15 mL/min/1.73 m²
- Pregnancy
- Absence of written informed consent
Who the study is looking for
- \- Age 18 years or older
- Biopsy-proven primary IgA nephropathy or primary focal segmental glomerulosclerosis
- Stable kidney function with an estimated glomerular filtration rate greater than 30 mL/min/1.73 m²
- Availability of serum and urine samples for soluble CD163 measurement
- Availability of relevant demographic, clinical, laboratory, histopathologic, and follow-up data
- For the healthy control group: age- and sex-matched individuals without known chronic disease and with normal kidney function
- Written informed consent
Age in the registry: 18 years to - · Sex: All · Accepts healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Bezmialem Vakif University Health Application and Research Center Coordinator of this site? Confirm its status | Istanbul | Turkey (Türkiye) | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.